

# Financial Tear Sheet

## CORPORATE PROFILE

Founded: 2014

Initial Public Offering: May 2016

Ticker / Market: "PLSE" traded on the Nasdaq Capital Market

Predecessor Companies Merged November 2014:

Bioelectromed, Inc. (founded 2000)

Nanoblate, Inc. (founded 2012)

Location: Burlingame, California

### Overview

Pulse Biosciences, Inc. is a medical technologies company developing commercial clinical applications for its proprietary Nano-Pulse Stimulation ("NPS") technology in dermatology, immune-oncology and veterinary medicine. The core of its applications is the PulseTx NPS systems, a multi-faceted platform medical device. The PulseTx is a proprietary pulse generation system capable of being "tuned" to specific therapeutic applications with therapies being applied with proprietary and treatment specific applicators.

Nano-Pulse Stimulation is Pulse Biosciences novel patented technology leveraging nano-second duration energy pulses to initiate naturally occurring biological processes at the cellular level. More than a decade of research has shown that the application of short duration NPS treatments initiates apoptosis, the process of programmed cell death that occurs in all multicellular organisms. NPS stimulation and the resulting natural cell death processes result in the elimination treated tumors and abnormal tissue. Further, research has demonstrated that the cell death processes initiated by NPS results in the presentation of previously unidentified tumor antigens to the immune system thereby simulating an immune response specific to the NPS treated tumor and abnormal tissue. This immune response resulting from NPS has been demonstrated to provide a vaccine like effect in conducted studies and is currently being explored for abscopal effect in malignant tumors.

Pulse Biosciences is pursuing applications for its technology in four key vertical markets:

*Immuno-Oncology:* NPS is potentially a frontline therapy in treating cancers, either as a standalone therapeutic application or in combination with existing and future biopharma therapies. Pre-clinical work in immune-oncology remain underway and clinical trials are planned to commence during 2017

*Dermatology:* Numerous potential targets exist for NPS in dermatology including seborrheic keratosis, non-malignant basal cell carcinoma, moles and warts. The non-thermal nature of NPS treatments affords favorable cosmetic outcomes in dermatologic treatments. Initial clinical study commencing fourth quarter 2016, additional trials planned for 2017.

*General Tissue Treatment:* General tissue treatment applications includes potential opportunities to leverage the PulseTx Systems' versatility to provide alternative, non-thermal, short-duration treatment modalities in large existing treatment markets. These large markets with established participants affords strategic partnership opportunities and an efficient regulatory approval pathway, via 510(k) clearance, for an initial commercial introduction of the NPS technology

to the clinic.

*Veterinary Medicine:* Limited existing treatment options, high prevalence of conditions believed treatable with NPS, and increasing demand for care for companion animals provide an opportunity for the unique treatment modality of the NPS technology. Well-established veterinary specific participants in the field afford the opportunity to address this rapidly growing market through strategic relationships with one or more partners.

*This presentation includes forward-looking statements relating to Pulse Biosciences, Inc.'s business, products, clinical studies, pre-clinical research and other future events and plans. These forward-looking statements are subject to significant risks as outlined under the section "Risk Factors" in the company's most recently filed Form 10Q or 10K available on the Company's website. Pulse Biosciences undertakes no obligation to update such forward looking statements.*

## UPCOMING EVENTS

There are currently no events scheduled.

## RECENT NEWS

06/06/17 - 3:59 p.m.

Pulse Biosciences Announces Treatment of First Patient in Study to Evaluate the Safety and Efficacy of Novel Nano-Pulse Stimulation Technology for Seborrheic Keratosis Lesions

---

05/04/17 - 1:31 p.m.

Pulse Biosciences Quarterly Investor Conference Call

---

04/17/17 - 6:34 p.m.

Pulse Biosciences to Host Quarterly Investor Conference Call on May 4, 2017

---

## STOCK PERFORMANCE

### TRI.TO (Common Stock)

Exchange	TSX (US Dollar)
Price	<b>\$61.29</b>
Change (%)	<b>▼ 0.15 (0.24%)</b>
Volume	270,677
52 Week Low	\$50.01
Market Cap	\$44,350,501,908
Rolling EPS	1.98
PE Ratio	30.98
Shares Outstanding	721,850,617



Data as of 06/27/17 1:07 p.m. ET

## SEC FILINGS

Filing Date	Form
06/09/17	4
06/05/17	SC 13G
05/24/17	4
05/22/17	S-8

Data provided by Nasdaq. Minimum 15 minutes delayed.